Carmen Pedro

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice.

Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice.

Journal: Leukemia & lymphoma

Published: December 28, 2022

Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.

Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.

Journal: American journal of hematology

Published: May 23, 2017

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Journal: International journal of molecular sciences

Published: February 10, 2017

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.

Journal: Annals of hematology

Published: August 29, 2016

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.

Journal: Oncotarget

Published: February 09, 2016

Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.

Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.

Journal: The Lancet. Haematology

Published: February 01, 2015

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.

Journal: Blood

Published: February 05, 2013

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

Journal: British journal of haematology

Published: December 05, 2012

Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?

Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?

Journal: Leukemia research

Published: September 28, 2012

Miliary and agminated papules as clinical presentation of a secondary cutaneous follicular lymphoma.

Miliary and agminated papules as clinical presentation of a secondary cutaneous follicular lymphoma.

Journal: Journal of the American Academy of Dermatology

Published: December 29, 2011

Showing 1-10 of 10

Last Updated: 09/26/2026